These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 36012442)

  • 41. Dual CRISPR-Cas3 system for inducing multi-exon skipping in DMD patient-derived iPSCs.
    Kita Y; Okuzaki Y; Naoe Y; Lee J; Bang U; Okawa N; Ichiki A; Jonouchi T; Sakurai H; Kojima Y; Hotta A
    Stem Cell Reports; 2023 Sep; 18(9):1753-1765. PubMed ID: 37625413
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A
    Echigoya Y; Trieu N; Duddy W; Moulton HM; Yin H; Partridge TA; Hoffman EP; Kornegay JN; Rohret FA; Rogers CS; Yokota T
    Int J Mol Sci; 2021 Dec; 22(23):. PubMed ID: 34884867
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Selection-free gene repair after adenoviral vector transduction of designer nucleases: rescue of dystrophin synthesis in DMD muscle cell populations.
    Maggio I; Stefanucci L; Janssen JM; Liu J; Chen X; Mouly V; Gonçalves MA
    Nucleic Acids Res; 2016 Feb; 44(3):1449-70. PubMed ID: 26762977
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Live-imaging of revertant and therapeutically restored dystrophin in the Dmd
    Petkova MV; Stantzou A; Morin A; Petrova O; Morales-Gonzalez S; Seifert F; Bellec-Dyevre J; Manoliu T; Goyenvalle A; Garcia L; Richard I; Laplace-Builhé C; Schuelke M; Amthor H
    Neuropathol Appl Neurobiol; 2020 Oct; 46(6):602-614. PubMed ID: 32573804
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A duchenne muscular dystrophy gene hot spot mutation in dystrophin-deficient cavalier king charles spaniels is amenable to exon 51 skipping.
    Walmsley GL; Arechavala-Gomeza V; Fernandez-Fuente M; Burke MM; Nagel N; Holder A; Stanley R; Chandler K; Marks SL; Muntoni F; Shelton GD; Piercy RJ
    PLoS One; 2010 Jan; 5(1):e8647. PubMed ID: 20072625
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Gene correction of a duchenne muscular dystrophy mutation by meganuclease-enhanced exon knock-in.
    Popplewell L; Koo T; Leclerc X; Duclert A; Mamchaoui K; Gouble A; Mouly V; Voit T; Pâques F; Cédrone F; Isman O; Yáñez-Muñoz RJ; Dickson G
    Hum Gene Ther; 2013 Jul; 24(7):692-701. PubMed ID: 23790397
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Quantitative Antisense Screening and Optimization for Exon 51 Skipping in Duchenne Muscular Dystrophy.
    Echigoya Y; Lim KRQ; Trieu N; Bao B; Miskew Nichols B; Vila MC; Novak JS; Hara Y; Lee J; Touznik A; Mamchaoui K; Aoki Y; Takeda S; Nagaraju K; Mouly V; Maruyama R; Duddy W; Yokota T
    Mol Ther; 2017 Nov; 25(11):2561-2572. PubMed ID: 28865998
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Antisense-induced exon skipping for duplications in Duchenne muscular dystrophy.
    Aartsma-Rus A; Janson AA; van Ommen GJ; van Deutekom JC
    BMC Med Genet; 2007 Jul; 8():43. PubMed ID: 17612397
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Generation of microRNA-378a-deficient hiPSC as a novel tool to study its role in human cardiomyocytes.
    Martyniak A; Andrysiak K; Motais B; Coste S; Podkalicka P; Ferdek P; Stępniewski J; Dulak J
    J Mol Cell Cardiol; 2021 Nov; 160():128-141. PubMed ID: 34329686
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Dystrophin quantification and clinical correlations in Becker muscular dystrophy: implications for clinical trials.
    Anthony K; Cirak S; Torelli S; Tasca G; Feng L; Arechavala-Gomeza V; Armaroli A; Guglieri M; Straathof CS; Verschuuren JJ; Aartsma-Rus A; Helderman-van den Enden P; Bushby K; Straub V; Sewry C; Ferlini A; Ricci E; Morgan JE; Muntoni F
    Brain; 2011 Dec; 134(Pt 12):3547-59. PubMed ID: 22102647
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A novel human muscle cell model of Duchenne muscular dystrophy created by CRISPR/Cas9 and evaluation of antisense-mediated exon skipping.
    Shimo T; Hosoki K; Nakatsuji Y; Yokota T; Obika S
    J Hum Genet; 2018 Mar; 63(3):365-375. PubMed ID: 29339778
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Targeted exon skipping as a potential gene correction therapy for Duchenne muscular dystrophy.
    Aartsma-Rus A; Bremmer-Bout M; Janson AA; den Dunnen JT; van Ommen GJ; van Deutekom JC
    Neuromuscul Disord; 2002 Oct; 12 Suppl 1():S71-7. PubMed ID: 12206800
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Efficient exon skipping by base-editor-mediated abrogation of exonic splicing enhancers.
    Qiu H; Li G; Yuan J; Yang D; Ma Y; Wang F; Dai Y; Chang X
    Cell Rep; 2023 Nov; 42(11):113340. PubMed ID: 37906593
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Antisense oligonucleotide-induced exon skipping restores dystrophin expression in vitro in a canine model of DMD.
    McClorey G; Moulton HM; Iversen PL; Fletcher S; Wilton SD
    Gene Ther; 2006 Oct; 13(19):1373-81. PubMed ID: 16724091
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Antisense-induced exon skipping restores dystrophin expression in DMD patient derived muscle cells.
    van Deutekom JC; Bremmer-Bout M; Janson AA; Ginjaar IB; Baas F; den Dunnen JT; van Ommen GJ
    Hum Mol Genet; 2001 Jul; 10(15):1547-54. PubMed ID: 11468272
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Intravenous infusion of an antisense oligonucleotide results in exon skipping in muscle dystrophin mRNA of Duchenne muscular dystrophy.
    Takeshima Y; Yagi M; Wada H; Ishibashi K; Nishiyama A; Kakumoto M; Sakaeda T; Saura R; Okumura K; Matsuo M
    Pediatr Res; 2006 May; 59(5):690-4. PubMed ID: 16627883
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Duchenne Muscular Dystrophy Myogenic Cells from Urine-Derived Stem Cells Recapitulate the Dystrophin Genotype and Phenotype.
    Falzarano MS; D'Amario D; Siracusano A; Massetti M; Amodeo A; La Neve F; Maroni CR; Mercuri E; Osman H; Scotton C; Armaroli A; Rossi R; Selvatici R; Crea F; Ferlini A
    Hum Gene Ther; 2016 Oct; 27(10):772-783. PubMed ID: 27530229
    [TBL] [Abstract][Full Text] [Related]  

  • 58. TRF2 rescues telomere attrition and prolongs cell survival in Duchenne muscular dystrophy cardiomyocytes derived from human iPSCs.
    Eguchi A; Gonzalez AFGS; Torres-Bigio SI; Koleckar K; Birnbaum F; Zhang JZ; Wang VY; Wu JC; Artandi SE; Blau HM
    Proc Natl Acad Sci U S A; 2023 Feb; 120(6):e2209967120. PubMed ID: 36719921
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Gene therapy for muscle disease.
    Miyagoe-Suzuki Y; Takeda S
    Exp Cell Res; 2010 Nov; 316(18):3087-92. PubMed ID: 20580709
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Correction of DMD in human iPSC-derived cardiomyocytes by base-editing-induced exon skipping.
    Wang P; Li H; Zhu M; Han RY; Guo S; Han R
    Mol Ther Methods Clin Dev; 2023 Mar; 28():40-50. PubMed ID: 36588820
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.